{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T21:58:20Z","timestamp":1770415100361,"version":"3.49.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.intimp.2014.04.018","type":"journal-article","created":{"date-parts":[[2014,5,5]],"date-time":"2014-05-05T03:00:13Z","timestamp":1399258813000},"page":"119-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model"],"prefix":"10.1016","volume":"21","author":[{"given":"Qingcui","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiping","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianying","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuiyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinhang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2014.04.018_bb0005","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","article-title":"Anti-TNF\u03b1 therapy of rheumatoid arthritis: what have we learned?","volume":"19","author":"Feldmann","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.intimp.2014.04.018_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbrc.2004.09.011","article-title":"Effects of IL-1beta on gene expression in human rheumatoid synovial fibroblasts","volume":"324","author":"Jeong","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.intimp.2014.04.018_bb0015","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.2174\/13816128113199990507","article-title":"Molecular hydrogen: new antioxidant and anti-inflammatory therapy for rheumatoid arthritis and related diseases","volume":"19","author":"Ishibashi","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.intimp.2014.04.018_bb0020","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/art.20001","article-title":"Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion","volume":"50","author":"Lubberts","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.intimp.2014.04.018_bb0025","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0952-7915(00)00269-7","article-title":"Immunotherapy for rheumatoid arthritis","volume":"13","author":"Taylor","year":"2001","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.intimp.2014.04.018_bb0030","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"358","author":"Lee","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2014.04.018_bb0035","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0889-857X(05)70206-4","article-title":"Pathogenesis of rheumatoid arthritis: the role of synoviocytes","volume":"27","author":"Yamanishi","year":"2001","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.intimp.2014.04.018_bb0040","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00002281-200105000-00004","article-title":"Antiinterleukin-1 therapy in rheumatic diseases","volume":"13","author":"Dayer","year":"2001","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.intimp.2014.04.018_bb0045","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4049\/jimmunol.162.1.577","article-title":"Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors","volume":"162","author":"Antonysamy","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2014.04.018_bb0050","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.4049\/jimmunol.160.7.3513","article-title":"IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1 and TNF-, by human macrophages","volume":"160","author":"Jovanovic","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2014.04.018_bb0055","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4049\/jimmunol.161.1.409","article-title":"Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines","volume":"161","author":"Chabaud","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2014.04.018_bb0060","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1084\/jem.183.6.2593","article-title":"T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines","volume":"183","author":"Fossiez","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2014.04.018_bb0065","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/art.1780380202","article-title":"Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis","volume":"38","author":"Arend","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.intimp.2014.04.018_bb0070","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0065-2776(08)60891-3","article-title":"Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis","volume":"64","author":"Feldmann","year":"1997","journal-title":"Adv Immunol"},{"key":"10.1016\/j.intimp.2014.04.018_bb0075","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebocontrolled trial","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2014.04.018_bb0080","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI5703","article-title":"IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis","volume":"103","author":"Kotake","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.intimp.2014.04.018_bb0085","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.intimp.2012.12.010","article-title":"Synergistic effects of interleukin-1\u03b2 and interleukin-17A antibodies on collagen-induced arthritis mouse model","volume":"15","author":"Yu","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.intimp.2014.04.018_bb0090","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/cdd.2009.74","article-title":"IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling","volume":"16","author":"Huang","year":"2009","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.intimp.2014.04.018_bb0095","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1046\/j.1365-2567.2001.01261.x","article-title":"Nitric oxide and bone","volume":"103","author":"Van'T Hof","year":"2001","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.intimp.2014.04.018_bb0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/clin.1994.1164","article-title":"Collagen-induced arthritis as a model of rheumatoid arthritis","volume":"73","author":"Durie","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.intimp.2014.04.018_bb0105","article-title":"Leukocytosis as a prognostic marker in the development of fetal inflammatory response syndrome","volume":"8","author":"Bartkeviciene","year":"2013"},{"issue":"3","key":"10.1016\/j.intimp.2014.04.018_bb0110","first-page":"204","article-title":"Monotherapy in rheumatoid arthritis","volume":"71(","author":"Scher","year":"2013","journal-title":"Bull Hosp Jt Dis"},{"key":"10.1016\/j.intimp.2014.04.018_bb0115","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/IJGM.S23920","article-title":"Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports","volume":"4","author":"Mahamid","year":"2011","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.intimp.2014.04.018_bb0120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jbspin.2009.10.011","article-title":"Anti-IL-1 molecules: new comers and new indications","volume":"77","author":"Molto","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.intimp.2014.04.018_bb0125","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1073\/pnas.89.16.7375","article-title":"Involvement of endogenous tumor necrosis factor and transforming growth factor \u03b2 during induction of collagen type II arthritis in mice","volume":"89","author":"Thorbecke","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.intimp.2014.04.018_bb0130","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/art.1780390513","article-title":"Anticytokine treatment of established type II collagen-induced arthritis in DBA\/1 mice: a comparative study using anti-TNF\u03b1, anti-IL-1 \u03b1\/\u03b2, and IL-1Ra","volume":"39","author":"Joosten","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.intimp.2014.04.018_bb0135","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2249.1994.tb06517.x","article-title":"Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment","volume":"95","author":"Van den Berg","year":"1994","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.intimp.2014.04.018_bb0140","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/art.20001","article-title":"Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion","volume":"50","author":"Lubberts","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.intimp.2014.04.018_bb0145","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1042\/BST0391226","article-title":"Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease","volume":"39","author":"Winyard","year":"2011","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.intimp.2014.04.018_bb0150","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/cdd.2009.74","article-title":"IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling","volume":"16","author":"Huang","year":"2009","journal-title":"Cell Death Differ"},{"issue":"6","key":"10.1016\/j.intimp.2014.04.018_bb0155","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10928-011-9219-z","article-title":"Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis","volume":"38","author":"Lon","year":"2011","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.intimp.2014.04.018_bb0160","first-page":"7","article-title":"The role of free radicals in the pathogenesis of rheumatoid arthritis","volume":"45","author":"Hadjigogos","year":"2003","journal-title":"Panminerva Med"},{"key":"10.1016\/j.intimp.2014.04.018_bb0165","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/jbmr.5650110303","article-title":"Nitric oxide and bone","volume":"11","author":"Evans","year":"1996","journal-title":"J Bone Miner Res"},{"issue":"293& 2940","key":"10.1016\/j.intimp.2014.04.018_bb0170","article-title":"Osteoclast inhibition: an action of nitric oxide not mediated by cyclic GMP","volume":"88","author":"MacIntyre","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.intimp.2014.04.018_bb0175","first-page":"104","article-title":"Nitric oxide: a cytokine induced regulator of bone resorption","author":"Ralston","year":"1995","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.intimp.2014.04.018_bb0180","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1172\/JCI117124","article-title":"Inducible production of nitric oxide in osteoblast like cells and in fetal bone explants is associated with suppression of osteoclastic bone resorption","volume":"93","author":"Lowik","year":"1994","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.intimp.2014.04.018_bb0185","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/art.1780400206","article-title":"Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity","volume":"40","author":"Tak","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"9285","key":"10.1016\/j.intimp.2014.04.018_bb0190","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"358","author":"Lee","year":"2001","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.intimp.2014.04.018_bb0195","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/ni0901-771","article-title":"Pathogenesis of arthritis: recent research progress","volume":"2","author":"Feldmann","year":"2001","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.intimp.2014.04.018_bb0200","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1084\/jem.183.6.2593","article-title":"T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines","volume":"183","author":"Fossiez","year":"1996","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.intimp.2014.04.018_bb0205","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.intimp.2014.04.018_bb0210","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0024-3205(97)00480-3","article-title":"Collagen induced arthritis, an animal model of autoimmunity","volume":"61","author":"Myers","year":"1997","journal-title":"Life Sci"},{"key":"10.1016\/j.intimp.2014.04.018_bb0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/clin.1994.1164","article-title":"Collagen-induced arthritis as a model of rheumatoid arthritis","volume":"73","author":"Durie","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.intimp.2014.04.018_bb0220","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1046\/j.1365-2249.1998.00529.x","article-title":"B cell-deficient mice do not develop type II collagen-induced arthritis (CIA)","volume":"111","author":"Svensson","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.intimp.2014.04.018_bb0225","doi-asserted-by":"crossref","first-page":"nn248","DOI":"10.1126\/science.285.5425.248","article-title":"HMG-1 as a late mediator of endotoxin lethality in mice","volume":"285","author":"Wang","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.intimp.2014.04.018_bb0295","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.intimp.2014.04.018_bb0230","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2014.04.018_bb0235","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2014.04.018_bb0240","doi-asserted-by":"crossref","first-page":"i103","DOI":"10.1136\/ard.59.suppl_1.i103","article-title":"Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis","volume":"59","author":"Schiff","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2014.04.018_bb0245","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.intimp.2014.04.018_bb0250","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.4049\/jimmunol.176.3.1908","article-title":"In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin","volume":"176","author":"Piskin","year":"2006","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.intimp.2014.04.018_bb0255","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ncprheum0047","article-title":"Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis","volume":"1","author":"Muller-Ladner","year":"2005","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.intimp.2014.04.018_bb0260","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00002281-200105000-00004","article-title":"Anti-interleukin-1 therapy in rheumatic diseases","volume":"13","author":"Dayer","year":"2001","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.intimp.2014.04.018_bb0265","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","article-title":"Role of cytokines in rheumatoid arthritis","volume":"14","author":"Feldmann","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.intimp.2014.04.018_bb0270","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1124\/pr.55.2.4","article-title":"Interleukin-10 therapy\u2014review of a new approach","volume":"55","author":"Asadullah","year":"2003","journal-title":"Pharmacol Rev"},{"issue":"5","key":"10.1016\/j.intimp.2014.04.018_bb0275","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jmb.2004.12.060","article-title":"Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2","volume":"346","author":"Ju\u00e1rez-Gonz\u00e1lez","year":"2005","journal-title":"J Mol Biol"},{"key":"10.1016\/j.intimp.2014.04.018_bb0280","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1748-717X-5-70","article-title":"Radiosensitization and growth inhibition of cancer cells mediated by an scFv antibody gene against DNA-PKcs in vitro and in vivo","volume":"5","author":"Du","year":"2010","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.intimp.2014.04.018_bb0285","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.molimm.2006.05.009","article-title":"The change of the scFv into the Fab format improves the stability and in vivo toxin neutralization capacity of recombinant antibodies","volume":"44","author":"Quintero-Hern\u00e1ndez","year":"2007","journal-title":"Mol Immunol"},{"issue":"2","key":"10.1016\/j.intimp.2014.04.018_bb0290","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.molimm.2013.08.002","article-title":"Pharmacological efficacy of anti-IL-1\u03b2 scFv. Fab and full-length antibodies in treatment of rheumatoid arthritis","volume":"57","author":"Qi","year":"2014","journal-title":"Mol Immunol"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576914001544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576914001544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T16:50:10Z","timestamp":1689180610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576914001544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1567576914001544"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2014.04.018","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2014.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}